Dapagliflozin ameliorates metabolic and hepatic outcomes in a mouse model of metabolic dysfunction-associated steatotic liver disease and diabetes
Acta Diabetologica · 2025
DOI: 10.1007/s00592-025-02488-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Diabetologica, 2025. Verfasst von Xiaoya Sun. Beteiligte Einrichtung: Department of Geriatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China. sunxiaoya2021@163.com. Hauptthemen laut MEDLINE: Glucosides, Benzhydryl Compounds, Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Beijing Tongren Hospital.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatrics, Beijing Tongren Hospital, Capital Medical University, Beijing, China. sunxiaoya2021@163.com.
Förderung
- Beijing Tongren Hospital
Zitieren
APA
Sun, X. (2025). Dapagliflozin ameliorates metabolic and hepatic outcomes in a mouse model of metabolic dysfunction-associated steatotic liver disease and diabetes. Acta Diabetologica. https://doi.org/10.1007/s00592-025-02488-1
Vancouver
Sun X. Dapagliflozin ameliorates metabolic and hepatic outcomes in a mouse model of metabolic dysfunction-associated steatotic liver disease and diabetes. Acta Diabetologica. 2025. doi:10.1007/s00592-025-02488-1
BibTeX
@article{Sun2025,
author = {Sun, Xiaoya},
title = {Dapagliflozin ameliorates metabolic and hepatic outcomes in a mouse model of metabolic dysfunction-associated steatotic liver disease and diabetes},
journal = {Acta Diabetologica},
year = {2025},
doi = {10.1007/s00592-025-02488-1}
}
EUVIMED